Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.06), $1.03 better than the analyst estimate of ($2.09). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $5.42 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Farmmi announces public offering of Class A ordinary shares
• MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c